Patients with pulmonary arterial hypertension who received bilateral lung or heart-lung transplants showed similar survival ...

UCLA scientists discovered that squamous cell skin cancer resists treatment by adapting its metabolism, switching from ...

In addition to being diagnosed more frequently in older patients, pulmonary arterial hypertension (PAH) is more frequently ...

BACKGROUND: The European Chronic Thromboembolic Pulmonary Hypertension registry (CTEPH), conducted between 2007 and 2012, reported the major impact of pulmonary endarterectomy (PEA) on the long-term ...

Mosliciguat, an inhaled once-daily PH medication, can reduce the resistance against blood flow in lung blood vessels, a Phase ...

Roivant Sciences Ltd. (NASDAQ:ROIV) created Pulmovant to in-license from Bayer AG (OTC:BAYRY) exclusive worldwide rights to ...

is a good start — and important for maintaining everything from our heart health to our weight — but there’s one thing experts don’t want overlooked: resistance training. Resistance ...

Roivant's latest biotech company launch – Pulmovant – has made its debut with a plan to develop a respiratory drug licensed ...

Under an in-license agreement worth up to $294 million, Roivant Sciences gains exclusive worldwide rights from Bayer to ...

Matt Gline is back with a new ‘vant’ company, after the Roivant Sciences CEO paid Bayer $14 million upfront for the rights to ...

TX45 was well-tolerated with no observed immunogenicity, and demonstrated a favorable PK/PD relationship which was used to identify doses for the ...

Chi Meng Fong, an analyst from Bank of America Securities, reiterated the Hold rating on Roivant Sciences (ROIV – Research Report). The ...